论文部分内容阅读
近期,全球领先的以药房主导的健康美容企业集团联合博姿股份有限公司与美国规模最大的连锁药店运营商沃尔格林公司(Walgreens)开启战略合作事宜,共同构建战略合作伙伴关系。根据协议,沃尔格林初期投资67亿美元资金和股份,获得联合博姿45%股权,并有权选择收购联合博姿剩余股权。此次交易将给双方带来怎样的改变?合并后的企业是否有意拓展中国市场呢?带着这些问题,记者采访了联合博姿执行董事长
Recently, the world’s leading pharmacy-led health and beauty business group Bozi Co., Ltd. and Walgreens, the largest U.S. drugstore chain operator, opened strategic cooperation to jointly establish a strategic partnership. According to the agreement, Walgreens initially invested 6.7 billion US dollars in funds and shares, get 45% stake in joint Bozi, and the right to choose to buy the remaining joint Bozi. The transaction will bring about what kind of changes both parties? After the merger of the business is intended to expand the Chinese market? With these issues, the reporter interviewed joint executive chairman Bo